The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Rosacea — Phenotypic Classification (2017 ROSCO/ROSacea COnsensus Update)

Modern phenotype-based classification of rosacea moving beyond traditional subtypes (erythematotelangiectatic, papulopustular, phymatous, ocular) to recognize individual clinical features (persistent centrofacial erythema as diagnostic, plus phenotypes — flushing, telangiectasia, papules-pustules, phyma, ocular features); guides personalized treatment with topical (azelaic acid, ivermectin, metronidazole, brimonidine, oxymetazoline, minocycline foam), oral (doxycycline subantimicrobial, isotretinoin), and procedural (vascular laser, IPL, electrosurgery) therapies.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dermatoloji department. Book Appointment →

What is Rosacea — Phenotypic Classification (2017 ROSCO/ROSacea COnsensus Update)?

Rosacea is a chronic inflammatory dermatosis primarily affecting central face, characterized by persistent erythema, flushing, telangiectasia, inflammatory papules and pustules, phymatous skin changes (most commonly nose — rhinophyma), and ocular involvement. Affects 5–10 percent of adults, peak age 30–60 years, predominantly fair-skinned (Fitzpatrick I-III, especially Celtic-Northern European descent — historically called 'curse of the Celts'). Women predominate overall but men have more severe phyma; ocular rosacea may occur without facial involvement.

Pathophysiology involves complex interplay of multiple mechanisms: (1) immune dysregulation with overactive innate immunity (elevated cathelicidin antimicrobial peptide LL-37 and abnormal kallikrein-5 serine protease processing, producing pro-inflammatory peptide fragments), neutrophilic and Th1/Th17 cytokine inflammation; (2) vascular hyperreactivity (impaired vasomotor tone with persistent vasodilation, increased VEGF, increased cutaneous blood flow); (3) neurovascular dysregulation (TRPV1 channel overexpression on cutaneous sensory neurons triggered by heat, capsaicin, alcohol, exercise; substance P, VIP, PACAP neuropeptide release); (4) Demodex folliculorum mite overgrowth (commensal in normal skin, increased density in rosacea; mite-derived antigens including Bacillus oleronius bacteria carried by Demodex drive cathelicidin response); (5) genetic predisposition (HLA-DRA, BTNL2 polymorphisms); (6) microbial dysbiosis on skin and possible H. pylori involvement (controversial); (7) barrier dysfunction with increased transepidermal water loss and tight junction dysfunction.

Traditional 2002 NRSEC (National Rosacea Society Expert Committee) classification recognized four subtypes: (1) Erythematotelangiectatic Rosacea (ETR) — persistent central facial erythema, flushing, telangiectasia, sensitive skin with stinging-burning; (2) Papulopustular Rosacea (PPR) — persistent erythema with inflammatory papules and pustules in central face, frequent overlap with ETR features; (3) Phymatous Rosacea (PhR) — thickened skin with irregular nodularity, predominantly affecting nose (rhinophyma) but also chin (gnathophyma), forehead (metophyma), ears (otophyma), eyelids (blepharophyma); typically occurs in men; (4) Ocular Rosacea (OR) — eye involvement: conjunctival injection, lid margin telangiectasia, blepharitis, recurrent chalazia, meibomian gland dysfunction, corneal involvement (keratitis, neovascularization, ulceration in severe cases). Traditional classification limited by extensive subtype overlap, false sequential implication, and inability to capture mixed phenotypes well.

2017 ROSCO (ROSacea COnsensus) and 2019 update introduced phenotype-based framework better aligned with clinical reality and individualized treatment: (a) Diagnostic phenotypes (presence alone diagnostic) — persistent centrofacial erythema (in absence of other identifiable cause for >12 weeks) OR phymatous changes; (b) Major phenotypes (any single one in addition is sufficient when persistent centrofacial erythema is absent) — flushing/transient erythema, telangiectasia (especially central facial), papules and pustules in central face, ocular manifestations (lid margin telangiectasia, blepharitis with collarettes, corneal involvement, recurrent chalazia); (c) Minor phenotypes (supportive but not diagnostic) — burning sensation, stinging, edema, dryness. This phenotype approach allows personalized treatment targeting specific clinical features.

Symptoms

Persistent central facial erythema (cheeks, nose, chin, forehead) — diagnostic feature
Flushing/transient erythema with triggers (heat, alcohol, spicy food, exercise, stress)
Telangiectasia (visible small blood vessels) on cheeks, nose, chin
Inflammatory papules and pustules in central face (without comedones — distinguishing from acne)
Phymatous skin changes — thickening with irregular nodularity (rhinophyma most common)
Burning, stinging, sensitive skin sensation
Facial edema (intermittent or persistent)
Dry skin and reduced barrier function
Ocular features: red eye, foreign body sensation, blurred vision, lid margin telangiectasia, blepharitis, recurrent chalazia (ocular rosacea)
Corneal involvement (keratitis, neovascularization, ulceration in severe ocular)
Triggers: sun, heat, hot drinks, alcohol, spicy food, exercise, stress, hot weather, cold wind, certain skincare products
Worsening with topical corticosteroids (steroid-induced rosacea-like dermatitis)

Risk Factors

Fair skin (Fitzpatrick I-III), Celtic-Northern European descent
Female sex (overall predominance; men more severe phyma)
Age 30–60 years (peak presentation)
Family history of rosacea
HLA-DRA, BTNL2 genetic variants
Demodex folliculorum mite overgrowth
Photoaging and chronic UV exposure
Tobacco smoking, alcohol use, dietary triggers (spicy food, hot drinks)
Helicobacter pylori infection (controversial)
Topical or systemic corticosteroid use (steroid-induced)
Inflammatory bowel disease (associated)
Cardiovascular disease and metabolic syndrome (associated)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent facial erythema with inflammatory papules and pustules
  • Flushing episodes with triggers and persistent redness
  • Visible telangiectasia on central face affecting appearance
  • Phymatous nose changes (rhinophyma) for cosmetic and functional concerns
  • Eye redness, foreign body sensation, blurred vision (ocular rosacea evaluation)
  • Recurrent chalazia or blepharitis with facial rosacea
  • Failed topical therapy after 8–12 weeks for systemic options
  • Sensitive skin with burning and stinging from common skincare products
  • Worsening with topical corticosteroid (steroid rosacea — emergent)
  • Severe inflammatory rosacea for laser, IPL, or isotretinoin consideration

Treatment Methods

01
Diagnostic workup: detailed history (onset, triggers — heat-alcohol-spicy food-exercise-stress, prior topical steroids, current skincare regimen, family history, ocular symptoms), full skin examination noting central facial erythema, telangiectasia, papules-pustules, phymatous changes, distribution; ocular examination (slit lamp if available — lid margin telangiectasia, meibomian gland dysfunction, conjunctival injection, corneal staining); apply 2017 ROSCO phenotype framework to characterize individual presentation; biopsy rarely needed (consider if atypical features, unilateral disease, suspected differential — lupus, sarcoidosis, perioral dermatitis); evaluate for differential diagnosis (acne vulgaris — comedones present, post-adolescent acne, perioral dermatitis — perioral and periorbital papules, seborrheic dermatitis — scaling in seborrheic distribution, photosensitive lupus, polymorphous light eruption, carcinoid syndrome flush, mastocytosis, demodicosis)
02
Skin care and lifestyle: gentle skin cleansing with non-soap mild cleanser (avoid astringents, alcohol, fragrance), daily emollient with ceramide and niacinamide, mineral-based broad-spectrum SPF 30+ daily (avoid chemical sunscreens which may irritate), trigger identification and avoidance (heat-cold extremes, alcohol especially red wine and spirits, spicy food, hot beverages, hot baths and showers, sauna), gentle exercise away from peak heat, stress management, smoking cessation, no chronic topical corticosteroids on face
03
Erythema and flushing-targeted: topical alpha-adrenergic agonists — brimonidine tartrate 0.33 percent gel (Mirvaso) — short-acting alpha2 agonist with 8–12 hour vasoconstriction effect (rebound erythema in 30 percent — counsel to start with small test area), oxymetazoline hydrochloride 1 percent cream (Rhofade) — preferred newer alpha1A agonist with less rebound; vascular laser therapy (pulsed dye laser PDL 595 nm, KTP 532 nm laser, Nd:YAG 1064 nm) for telangiectasia and persistent erythema (multiple sessions over weeks-months); intense pulsed light (IPL) — broadband light for telangiectasia and erythema
04
Papules and pustules-targeted: topical first-line — azelaic acid 15 percent gel or 20 percent cream twice daily (anti-inflammatory and anti-Demodex effects, well-tolerated), metronidazole 0.75–1 percent gel-cream-lotion once or twice daily (anti-inflammatory effect; established and inexpensive), ivermectin 1 percent cream (Soolantra) once daily (anti-Demodex and anti-inflammatory; superior efficacy in many studies), minocycline 1.5 percent foam (Zilxi) once daily (newer topical antibiotic), permethrin 5 percent cream (anti-Demodex if mite-driven); oral — subantimicrobial dose doxycycline 40 mg modified release once daily (Oracea — anti-inflammatory at this dose, no significant antimicrobial effect, no resistance development, FDA approved specifically for rosacea papulopustular), conventional dose doxycycline 100 mg daily for severe (short course), oral minocycline 100 mg daily if doxycycline-intolerant (rare hypersensitivity, drug-induced lupus, hyperpigmentation), erythromycin or azithromycin in pregnancy/lactation; isotretinoin 0.25–0.5 mg/kg/day for severe refractory papulopustular and phymatous (lower dose than acne, longer duration; pregnancy precautions same as acne, monitoring, iPLEDGE)
05
Phymatous changes: oral isotretinoin (most effective in early phase; reduces sebaceous gland hyperplasia and prevents progression), surgical management for established phyma — electrosurgery (loop excision, dermabrasion), CO2 laser ablation, scalpel sculpting with second-intention healing or split-thickness graft, surgical excision and reconstruction; cryotherapy for early changes; combine with continued isotretinoin maintenance
06
Ocular rosacea: lid hygiene cornerstone — warm compresses 5–10 minutes twice daily, gentle lid massage, dilute baby shampoo or commercial lid cleanser; preservative-free artificial tears 4–8 times daily; topical cyclosporine 0.05 percent (Restasis) twice daily for chronic; topical or oral azithromycin (1 percent solution; oral 250–500 mg twice weekly); oral doxycycline 100 mg daily or subantimicrobial 40 mg once daily; intense pulsed light (IPL) for meibomian gland dysfunction; tea tree oil products (anti-Demodex on lashes — terpinen-4-ol active component); cyclosporine ointment 0.1 percent for severe corneal involvement; ophthalmology referral for severe ocular involvement
07
Avoidance of triggers: documented food and environmental triggers (rosacea diary helpful), graded behavioral modifications, sun protection paramount (UV is major trigger and disease accelerator), avoid hot showers and saunas, avoid topical irritants and fragrance
08
Adjunctive: topical antioxidants (vitamin C, niacinamide) for barrier support, omega-3 fatty acid supplementation, dietary modifications (low salicylate or histamine-restricted diet in select patients), psychological support for visible disease and self-image impact
09
Newer and emerging: topical Janus kinase (JAK) inhibitors (in research), mast cell stabilizers, topical β-blockers (timolol — anecdotal for flushing), botulinum toxin (intradermal microinjections for flushing and erythema in research), laser-assisted drug delivery, photodynamic therapy
10
Long-term: chronic relapsing-remitting course requiring lifelong management; regular dermatology follow-up every 3–6 months for active disease, annual when stable; ocular surveillance if ocular component; recognize rosacea fulminans (rosacea conglobata, pyoderma faciale) — emergent severe form requiring oral isotretinoin and corticosteroids; multidisciplinary care (dermatology, ophthalmology) for complex cases; patient support groups (National Rosacea Society)

Which Department to Visit?

You can visit our Dermatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dermatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Eczema (Atopic Dermatitis)

Dermatoloji

Atopic dermatitis is a chronic skin disease commonly seen especially in children, flaring with genetic predisposition and environmental triggers.

Psoriasis

Dermatoloji

Psoriasis is an autoimmune disease in which skin cells proliferate rapidly when the immune system mistakenly attacks the skin, leading to thick scaly lesions.

Acne

Dermatoloji

Acne is a skin disease resulting from clogging of hair follicles with oil and dead skin cells, commonly seen in adolescence but can occur at any age.

Rosacea

Dermatoloji

Rosacea is a chronic inflammatory facial skin disease characterized by recurrent flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules. Phymatous change and ocular involvement may complicate advanced disease.

Urticaria (Hives)

Dermatoloji

Urticaria is a skin condition with sudden pink-red wheals and intense itching that may follow an acute or chronic course.

Skin Fungal Infections

Dermatoloji

Skin fungal infections are common, contagious skin diseases caused by dermatophytes and yeast fungi colonizing the upper layers of the skin.

Hair Loss (Alopecia)

Dermatoloji

Alopecia is a general term for hair loss that can be genetic, hormonal, autoimmune, or nutritional; early intervention can slow progression.

Vitiligo

Dermatoloji

Vitiligo is an acquired autoimmune disease in which CD8+ T cells destroy melanocytes, producing well-demarcated depigmented patches. Early, sustained treatment can induce repigmentation and prevent progression; psychosocial impact warrants holistic care.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.